(Q37865068)

24 August 2017

1 reference

title

Weight gain associated with taking psychotropic medication: an integrative review (English)

1 reference

24 August 2017

1 reference

2

Kim Foster

1 reference

24 August 2017

Andrea McCloughen

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

18 February 2011

1 reference

International Journal of Mental Health Nursing

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

202-222

1 reference

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Practice parameter for the assessment and treatment of children and adolescents with depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Practice parameter on the use of psychotropic medication in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

The impact of weight gain on quality of life among persons with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Distress with medication side effects among persons with severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Psychotropic medication utilization in a child and adolescent mental health service

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Obesity among individuals with serious mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Mood disorders: cardiovascular and diabetes comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

A comparison of clinician and patient concerns about antipsychotic side effects: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Outcome evaluation of a structured educational wellness program in patients with severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Early predictors of substantial weight gain in bipolar patients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Perceptions of barriers and benefits to physical activity among outpatients in psychiatric rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Obesity in patients with severe mental illness: overview and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Multi-modal weight control intervention for people with persistent mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Medical co-morbidity risk factors and barriers to care for people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Severe mental illness and risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Initial investigation of behavioral activation therapy for co-morbid major depressive disorder and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Increasing lifestyle physical activity in patients with depression or other serious mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Weight change in treatment with olanzapine and a psychoeducational approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

An overview of obesity in children with psychiatric disorders taking atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Body mass index and quality of life in community-dwelling patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Metabolic side effects of antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

The integrative review: updated methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Understanding the new and evolving profile of adverse drug effects in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1447-0349.2010.00721.X

10.1111/J.1447-0349.2010.00721.X

21 January 2018

Identifiers

DOI

1 reference

release_2kpwerkf6rccppwltqzpwa6rim

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2kpwerkf6rccppwltqzpwa6rim

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference